|
Ulrik Spork is a Senior Partner in Novo Ventures; he led the establishment of the new venture investment activities in Novo A/S at its start in 1999. Prior to the formation of Novo A/S, Ulrik spent nine years in Novo Nordisk A/S from 1994 as Director of Corporate Development. In this capacity he was involved in the corporation's strategy building and restructuring process and managed a number of acquisitions and divestments. Furthermore he was in charge of Novo Nordisk's equity investments in biotech companies and spinouts, including the $150 million private placement in ZymoGenetics, Inc. Prior to joining the Novo group in 1991, he spent seven years involved in product development, marketing and international sales in the medical electronics field. He presently serves on the board of directors of Corus Pharma, Inc. (Seattle, USA) and BioImage A/S (Soeborg, Denmark). In addition he is chairman of the Danish Venture Capital and Private Equity Association (DVCA). Mr. Spork holds a MSC in Engineering from Technical University of Copenhagen and a BSC in International Economics from the Copenhagen Business School. | 